<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and three consecutive asymptomatic anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> (aPL) antibody-positive carriers, taking aspirin (n=75) or not (n=28), were studied retrospectively to determine whether aspirin could provide primary prevention of anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (APS) symptoms </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients positive for anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies (aCL; &gt;25 UGPL or UMPL) and/or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> anti-coagulant were followed for a mean of 64+/-24.7 months.Among aPL-positive patients, 37 had <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), 20 had <z:hpo ids='HP_0003645'>prolonged activated partial thromboplastin times</z:hpo>, 19 had <z:e sem="disease" ids="C0810058" disease_type="Disease or Syndrome" abbrv="">other connective tissue diseases</z:e>, 16 had <z:hpo ids='HP_0001973'>autoimmune thrombocytopenia</z:hpo> (AIT), 11 had diverse diseases </plain></SENT>
<SENT sid="2" pm="."><plain>Nineteen patients experienced thrombotic event(s) during follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical features, biological parameters and hydroxychloroquine use were comparable for the two groups, but thrombotic events differed (log-rank test; P=0.02) </plain></SENT>
<SENT sid="4" pm="."><plain>Four of the 10 SLE patients not taking aspirin developed <z:mp ids='MP_0005048'>thrombosis</z:mp> compared with 3/27 SLE patients taking aspirin (log-rank test; P=0.03) </plain></SENT>
<SENT sid="5" pm="."><plain>Anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> -positive patients with AIT developed fewer thromboses while taking aspirin (log-rank test; P=0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, aPL-positive SLE and AIT patients should take aspirin to prevent APS manifestations </plain></SENT>
<SENT sid="7" pm="."><plain>Prospective therapeutic trials are needed to confirm aspirin's prophylactic role in such patients </plain></SENT>
</text></document>